| Abstract |
This report describes the status of work under contract DAMD17-86-C-6150. Analytical methodologies were under development for the determination of the concentrations of the anti-viral drug, ribavirin, and WR 249,992 in plasma; the anti-malarial drug, arteether, and dihydroginghaosu in biological fluids, the anti-malarial drug, halofantrine, and its metabolite, WR 178,460, in blood and plasma; the anti-leishmanial compound, WR 6026 in blood and plasma and the 4-hydroxymethyl metabolite of WR 6026 (WR 211,789) in biological fluids; mefloquine in blood and the carboxyl metabolite of mefloquine, WR 160,972, in biological fluids. Study reports were submitted for the ribavirin and halofantrine methods. Routine assays for nine studies were underway during the fifth year of the contract for analysis of plasma and blood for halofantrine and WR 178,460; plasma and infusates for pyridostigmine; blood for mefloquine; and plasma for WR 6026 and WR 211,789. |
